Neurofunctional Basis of Emotion Processing: Clinical, Genetic, Biological and Imaging Study in Patients With Schizophrenia and Healthy Relatives of Patients in Comparison With a Control Group
| Registry | NCT02834208, acronym SCHIZOIMAGEN |
|---|---|
| Status | Unknown |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: none |
| Enrollment | 105 (Estimated) |
| Sponsor | Assistance Publique Hopitaux De Marseille (Other) |
| Conditions | Schizophrenia |
| Interventions | MRI (Magnetic resonance imaging), Polymorphism (SNP in DNA), quantitative measures of mRNA, Neuropsychological assessment (Other, genetic) |
| Dates | start 2015-12-01, primary completion 2018-12-01 (estimated), completion 2019-06-01 (estimated), first posted 2016-07-15, last updated 2016-08-30 |
| Locations | 1 site in France |
Related Papers Related Patents Related Grants Related Experts
All trials for Schizophrenia All trials of MRI (Magnetic resonance imaging) All trials of Polymorphism (SNP in DNA)
Schizophrenia is an invalidating psychiatric illness with a strong genetic component characterized by abnormal processing of emotional information. This alteration in emotion processing has been described in acute as well as in remission phases of the illness. It has also been found in healthy relatives of patients with schizophrenia and in subjects at high risk of psychosis. Thus, alterations in emotional information processing are not only linked to the prognosis but can also be considered as a marker of vulnerability of schizophrenia. In addition, schizophrenia patients differ from healthy controls in neural activity in brain regions implicated in emotions processing. However, interpretation of findings in patients is limited by confounding factors, such as antipsychotic treatments or alterations due to the course of illness. Also, there is no data concerning genetic factors (polymorphisms or gene expression) underlying these patterns of cerebral activation in emotion information processing.
So, the main objective of this study is to compare the cerebral activity of schizophrenia patients to that of healthy siblings and healthy controls in an emotional processing task.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Schizophrenia subjects | Experimental | Other: MRI (Magnetic resonance imaging); Genetic: Polymorphism (SNP in DNA); Genetic: quantitative measures of mRNA; Other: Neuropsychological assessment | 35 patients suffering from schizophrenia |
| Healthy siblings | Other | Other: MRI (Magnetic resonance imaging); Genetic: Polymorphism (SNP in DNA); Genetic: quantitative measures of mRNA; Other: Neuropsychological assessment | 35 healthy siblings of the patients suffering from schizophrenia |
| Healthy controls | Other | Other: MRI (Magnetic resonance imaging); Genetic: Polymorphism (SNP in DNA); Genetic: quantitative measures of mRNA; Other: Neuropsychological assessment | 35 healthy "controls "patients |
Sex: All, ages: 18 Years to 45 Years
Inclusion Criteria: * Male or female participant, right-handed, aged from 18 to 45 years old * Haven given their written consent * DSM-5 (Diagnostic and Statistical Manual of Mental Disorders version 5) diagnosis of schizophrenia * Remitted phase (criteria of Andreasen) * Stable doses of antipsychotics during the last 6 weeks * No severe somatic illness * Normal clinical exam * Inscription to the social security Exclusion Criteria: * Women in genitally active period without contraception * Women pregnant or breast feeding * Participants presenting a severe somatic /neurologic condition * Present/history in the last year of alcohol or drug abuse * Participating in another clinical study or still in period of exclusion of a previous clinical trial * Contraindication to an MRI test (metallic foreign body, pacemaker, heart valve, chirurgical clip, claustrophobia…)
| Facility | City | Country | Status |
|---|---|---|---|
| Pôle Psychiatrie Centre CHU Conception, Marseille, APHM | Marseille | France | Recruiting |